Tag: Dr Daniel Adelman

AR101

Phase 3 Trial Data Demonstrates Consistent Safety and Efficacy of AR101...

“Results of the European ARTEMIS trial provide further clinical validation of the safety and efficacy of AR101 for children and adolescents with peanut allergy.”
AR101

European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...

Company Intends to Submit European MAA in Mid-2019.
AR101

Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...

AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.

Connect with Us

40,035FansLike
960FollowersFollow
2,765FollowersFollow
5,603FollowersFollow
42SubscribersSubscribe